bioAffinity signs AvMEDICAL distribution deal for CyPath Lung in federal healthcare market
BIAF•CyPath Lung test overview
CyPath Lung is a noninvasive test for assessing indeterminate pulmonary nodules; it is run by bioAffinity’s Precision Pathology Laboratory Services.
Distribution agreement expands federal market access
bioAffinity Technologies entered a distribution agreement with AvMEDICAL to sell CyPath Lung across the US federal healthcare market.
The deal targets government procurement channels, including the Department of Veterans Affairs, to expand access to the lung-cancer risk test. AvMEDICAL will market CyPath Lung to federal customers using its contracting vehicles, aiming to simplify purchasing and speed adoption.
